A recent study on a large cohort of of iCCA patients (n=496) based on occurrence of mutations in IDH, KRAS and TP53 genes, revealed unique mutational, structural and epigenetic features, which could facilitate prediction of therapeutic sensitivity for each iCCA patient, by evaluating individual genotyping [173]. This evidence concerns the gene KRAS and infantile convulsions and choreoathetosis.